厄洛替尼联合抗血管生成药物对比厄洛替尼单药一线治疗EGFR突变晚期非小细胞肺癌的疗效

    The Efficacy of Erlotinib Combined with Anti-Angiogenesis Treatment in Comparison with Erlotinib Alone as First-Line Treatment of EGFR-Mutated Advanced Non-Small Cell Lung Cancer

    /

    返回文章
    返回